Former OpenAI science lead Kevin Weil has launched Warp Sciences, a new AI startup focused on automating lab work for drug discovery. The company, which trains robots to make and test promising compounds identified by researchers, has raised $215 million at an $865 million valuation, according to Weil, who announced the startup and funding on
Lightspeed is sharpening its India strategy around AI, targeting $250 million for a new early-stage fund as the venture firm bets the technology will drive the next wave of startups in one of the world’s largest markets. The Silicon Valley venture firm is already a major investor in AI companies including Anthropic, xAI, and Databricks.
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the maker of ChatGPT to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.
